International Journal of Drug Policy
Volume 21, Issue 2 , Pages 122-124 , March 2010

Methadone as HIV prevention: High Volume Methadone Sites to decrease HIV incidence rates in resource limited settings

Received 30 September 2009 ,Revised 12 October 2009 ,Accepted 14 October 2009.

References 

  1. Abdala N, Carney JM, Durante AJ, Klimov N, Ostrovski D, Somlai AM, et al. Estimating the prevalence of syringe-borne and sexually transmitted diseases among injection drug users in St Petersburg, Russia. International Journal of STD & AIDS. 2003;14(10):697–703
  2. Anonymous . Risk behaviors for HIV transmission among intravenous-drug users not in drug treatment—United States, 1987–1989. Morbidity & Mortality Weekly Report. 1990;39(16):273–276
  3. Ball J, Ross A. The effectiveness of methadone maintenance treatment. New York: Springer-Verlag; 1991;
  4. Battjes RJ, Pickens RW, Amsel Z. HIV infection and AIDS risk behaviors among intravenous drug users entering methadone treatment in selected U.S. cities. Journal of Acquired Immune Deficiency Syndromes. 1991;4(11):1148–1154
  5. Bruce R, Altice F. Clinical care of the HIV-infected drug user. Infectious Disease Clinics of North America. 2007;21(1):149–179ix
  6. Buning EC, Coutinho RA, van Brussel GH, van Santen GW, van Zadelhoff AW. Preventing AIDS in drug addicts in Amsterdam. Lancet. 1986;1(8495):1435
  7. Caiaffa WT, Proietti FA, Carneiro-Proietti AB, Mingoti SA, Doneda D, Gandolfi D, et al. The dynamics of the human immunodeficiency virus epidemics in the south of Brazil: Increasing role of injection drug users. Clinical Infectious Diseases. 2003;37(Suppl 5):S376–381
  8. Davstad I, Stenbacka M, Leifman A, Romelsjo A. An 18-year follow-up of patients admitted to methadone treatment for the first time. Journal of Addictive Diseases. 2009;28(1):39–52
  9. Dolan K, Hall W, Wodak A. Methadone maintenance reduces injecting in prison [see comment]. BMJ. 1996;312(7039):1162
  10. Donny EC, Walsh SL, Bigelow GE, Eissenberg T, Stitzer ML. High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans. Psychopharmacology. 2002;161(2):202–212
  11. Doran CM, Shanahan M, Mattick RP, Ali R, White J, Bell J. Buprenorphine versus methadone maintenance: A cost-effectiveness analysis. Drug and Alcohol Dependence. 2003;71(3):295–302
  12. Gossop M, Marsden J, Stewart D, Rolfe A. Patterns of improvement after methadone treatment: 1 year follow-up results from the National Treatment Outcome Research Study. Drug and Alcohol Dependence. 2000;60(3):275–286
  13. Hall W, Darke S, Ross M, Wodak A. Patterns of drug use and risk-taking among injecting amphetamine and opioid drug users in Sydney, Australia. Addiction. 1993;88(4):509–516
  14. Himelhoch S, Chander G, Fleishman JA, Hellinger J, Gaist P, Gebo KA. Access to HAART and utilization of inpatient medical hospital services among HIV-infected patients with co-occurring serious mental illness and injection drug use. General Hospital Psychiatry. 2007;29(6):518–525
  15. Kerr T, Wodak A, Elliott R, Montaner JS, Wood E. Opioid substitution and HIV/AIDS treatment and prevention. Lancet. 2004;364(9449):1918–1919
  16. Loimer N, Werner E, Presslich O. Sharing spoons: A risk factor for HIV-1 infection in Vienna. British Journal of Addiction. 1991;86(6):775–778
  17. Lucas GM, Mullen BA, Weidle PJ, Hader S, McCaul ME, Moore RD. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clinical Infectious Diseases. 2006;42(11):1628–1635
  18. Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: A meta-analysis. Addiction. 1998;93(4):515–532
  19. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: A systematic review. Lancet. 2008;372(9651):1733–1745
  20. McCurdy SA, Ross MW, Kilonzo GP, Leshabari MT, Williams ML. HIV/AIDS and injection drug use in the neighborhoods of Dar es Salaam, Tanzania. Drug and Alcohol Dependence. 2006;82(Suppl.1):S23–27
  21. Metzger DS, Woody GE, McLellan AT, O’Brien CP, Druley P, Navaline H, et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: An 18-month prospective follow-up. Journal of Acquired Immune Deficiency Syndromes. 1993;6(9):1049–1056
  22. Murray JB. Effectiveness of methadone maintenance for heroin addiction. Psychological Reports. 1998;83(1):295–302
  23. Newman RG. Narcotic addiction and methadone treatment in Hong Kong: Lessons for the United States. Journal of Public Health Policy. 1985;6(4):526–538
  24. Qian HZ, Hao C, Ruan Y, Cassell HM, Chen K, Qin G, et al. Impact of methadone on drug use and risky sex in China. Journal of Substance Abuse Treatment. 2008;34(4):391–397
  25. Roux P, Carrieri MP, Villes V, Dellamonica P, Poizot-Martin I, Ravaux I, et al. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: Evidence from the MANIF2000 cohort study. Addiction. 2008;103(11):1828–1836
  26. Saelim A, Geater A, Chongsuvivatwong V, Rodkla A, Bechtel GA. Needle sharing and high-risk sexual behaviors among IV drug users in Southern Thailand. AIDS Patient Care & STDS. 1998;12(9):707–713
  27. Schwartz RP, Jaffe JH, Highfield DA, Callaman JM, O’Grady KE. A randomized controlled trial of interim methadone maintenance: 10-Month follow-up. Drug and Alcohol Dependence. 2007;86(1):30–36
  28. Stenbacka M, Leifman A, Romelsjo A. The impact of methadone treatment on registered convictions and arrests in HIV-positive and HIV-negative men and women with one or more treatment periods. Drug and Alcohol Review. 2003;22(1):27–34
  29. Tegger MK, Crane HM, Tapia KA, Uldall KK, Holte SE, Kitahata MM. The effect of mental illness, substance use, and treatment for depression on the initiation of highly active antiretroviral therapy among HIV-infected individuals. AIDS Patient Care & STDS. 2008;22(3):233–243
  30. Yancovitz SR, Des Jarlais DC, Peyser NP, Drew E, Friedmann P, Trigg HL, et al. A randomized trial of an interim methadone maintenance clinic. American Journal of Public Health. 1991;81(9):1185–1191
  31. Zhang C, Yang R, Xia X, Qin S, Dai J, Zhang Z, et al. High prevalence of HIV-1 and hepatitis C virus coinfection among injection drug users in the southeastern region of Yunnan, China. Journal of Acquired Immune Deficiency Syndromes. 2002;29(2):191–196

PII: S0955-3959(09)00130-3

doi: 10.1016/j.drugpo.2009.10.004

International Journal of Drug Policy
Volume 21, Issue 2 , Pages 122-124 , March 2010

Article Tools